共 50 条
- [21] Results of a unicenter randomized study of the safety and efficiency of docetaxel chemotherapy before radical prostatectomy in patients with intermediate-and high-risk prostate cancer: An 11.4-year follow-upONKOUROLOGIYA, 2014, 10 (04): : 52 - 61Nosov, A. K.Petrov, S. B.Reva, S. A.Mamizhev, E. M.Novikov, R. V.Veliev, E. I.Moiseenko, V. M.
- [22] Total estrogen blockade and chemotherapy in high-risk premenopausal early breast cancer (BC): Long-term follow-up of a phase II study.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Recchia, FrancescoCandeloro, GiampieroCesta, AlisiaNecozione, StefanoRea, SilvioBratta, MassimoHoo, William SooCantor, Thomas
- [23] Long-term tolerance of neoadjuvant docetaxel/estramustine chemotherapy in patients with high-risk localized prostate cancer treated at IGR in the GETUG 12 phase III trialJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)Bosset, Pierre-OlivierAlbiges, LaurenceLaplanche, AgnesMassard, ChristopheLoriot, YohannDi Palma, MarioFizazi, Karim
- [24] Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 TrialEUROPEAN UROLOGY, 2023, 84 (02) : 156 - 163Sartor, OliverKarrison, Theodore G.Sandler, Howard M.Gomella, Leonard G.Amin, Mahul B.Purdy, JamesMichalski, Jeff M.Garzotto, Mark G.Pervez, NadeemBalogh, Alexander G.Rodrigues, George B.Souhami, LuisReaume, M. NeilWilliams, Scott G.Hannan, RaquibulJones, Christopher U.Horwitz, Eric M.Rodgers, Joseph P.Feng, Felix Y.Rosenthal, Seth A.
- [25] Ki-67, topoisomerase IIα and miR-221 have a limited prostate cancer risk stratification ability on a medium-term follow-up: results of a high-risk radical prostatectomy cohortTRANSLATIONAL ANDROLOGY AND UROLOGY, 2022, : 1271 - 1281Marra, GiancarloOderda, MarcoCalleris, GiorgioMarquis, AlessandroPeretti, FedericaZitella, AndreaMoschini, MarcoSanchez-Salas, RafaelKarnes, Robert JeffreyKneitz, BurkhardSpahn, MartinPacchioni, DonatellaGontero, Paolo
- [26] Abiraterone, Androgen Deprivation Therapy, and Radiotherapy for Localized Intermediate/High Risk Prostate Cancer: Long-Term Follow-Up of the RAD1 Phase 2 TrialINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E228 - E229Liao, J. J.Mostaghel, E.Russell, K. J.Dalkin, B.Ellis, W.Lin, D.Wright, J.Schade, G.Nyame, Y. A.Yu, E. Y.Nelson, P.Grivas, P.Schweizer, M.Cheng, H. H.Yezefski, T.Hawley, J. E.Chen, J.Weg, E. S.Nguyen, M. H.Montgomery, B.
- [27] Long-term follow-up assessment of a HER-2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patientsJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Gates, J. D.Benavides, L. C.Carmichael, M. G.Holmes, J. P.Hueman, M. T.Mittendorf, E. A.McLeod, D. G.Ponniah, S.Peoples, G. E.
- [28] Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trialLANCET ONCOLOGY, 2016, 17 (08): : 1127 - 1136Mateos, Maria-VictoriaHernandez, Miguel-TeodoroGiraldo, Pilarde la Rubia, Javierde Arriba, FelipeLopez Corral, LuciaRosinol, LauraPaiva, BrunoPalomera, LuisBargay, JoanOriol, AlbertProsper, FelipeLopez, JavierArguinano, Jose-MariaQuintana, NuriaGarcia, Jose-LuisBlade, JoanLahuerta, Juan-JoseSan Miguel, Jesus-F
- [29] A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upBone Marrow Transplantation, 2012, 47 : 1448 - 1454K A KasowC F StewartR C BarfieldN L WrightC LiD K SrivastavaW LeungE M HorwitzL C BowmanR HandgretingerG A Hale
- [30] A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upBONE MARROW TRANSPLANTATION, 2012, 47 (11) : 1448 - 1454Kasow, K. A.Stewart, C. F.Barfield, R. C.Wright, N. L.Li, C.Srivastava, D. K.Leung, W.Horwitz, E. M.Bowman, L. C.Handgretinger, R.Hale, G. A.